Feature | September 02, 2014

Study Confirms CT Lung Cancer Screening is Cost-Effective: Full Medicare Coverage Should Follow, Says ACR

Study Confirms CT Lung Cancer Screening is Cost-Effective: Full Medicare Coverage Should Follow, Says ACR

September 2, 2014 — An actuarial cost-benefit analysis published in the August issue of American Health and Drug Benefits shows that use of U.S. Preventive Services Task Force (USPSTF) lung cancer screening recommendations in high-risk Medicare beneficiaries is cost-effective, potentially answering any questions regarding the effectiveness, infrastructure and cost effectiveness of low-dose computed tomography (CT) screening.

This latest analysis echoes a 2012 study published in Health Affairs that found low-dose CT lung cancer screening is cost-effective in high-risk, commercially insured people. National Lung Screening Trial (NLST) data presented to the National Institutes of Health (NIH) confirmed the test is cost effective — particularly compared to other screening programs. Other published data show the test is more cost-effective than automobile seatbelts/airbags.

“CT lung cancer screening is cost-effective and significantly reduces lung cancer deaths. Published results show no undue or lasting patient anxiety from the screening process. It is time for Medicare to cover CT lung cancer screening,” said Ella Kazerooni, M.D., FACR, chair of the American College of Radiology (ACR) Lung Cancer Screening Committee and ACR Thoracic Imaging Panel.

Significant lung cancer screening infrastructure is growing. The ACR Lung Cancer Screening Center program helps ensure these exams are provided safely and effectively. Lung-RADS standardizes CT lung cancer screening reporting and management, aids lung CT interpretation and supports outcomes monitoring.

The Affordable Care Act requires private insurers to cover medical procedures that receive a grade of “B” or higher from the USPSTF without a co-pay. The ACA does not specify that Medicare beneficiaries receive full coverage for these services. CT lung cancer screening is deemed an Essential Health Benefit, covered by many private health insurers, while Medicare beneficiaries have lesser access to these exams and increased risk of lung cancer death due to lack of coverage.

“Lung cancer is the nation’s leading cancer killer, annually taking more lives than breast, prostate and colon cancer combined. CT lung cancer screening could save up to 30,000 people each year. Medicare needs to help doctors save lives by fully covering these exams,” concluded Kazerooni.

For more information: www.acr.org

Related Content

According to the CDC, if you are fully vaccinated you can start doing many things that you had stopped doing because of the pandemic. Infographic courtesy of the CDC.

According to the CDC, if you are fully vaccinated you can start doing many things that you had stopped doing because of the pandemic. Infographic courtesy of the CDC.

News | Coronavirus (COVID-19) | May 13, 2021
May 13, 2021 — The Centers for Disease Control and Prevention (CDC) just
Estimates of excess deaths, defined as the number of persons who have died from all causes, above the expected number of deaths for a given place and time, can provide a comprehensive account of mortality likely related to the COVID-19 pandemic, including deaths that are both directly and indirectly associated with COVID-19.
News | Coronavirus (COVID-19) | May 13, 2021
May 13, 2021 — Estimates of excess deaths, defined as the number of persons who have died from all causes, above the
National Imaging Solutions, a recognized leader in medical imaging and radiology solutions, announced it has acquired DynaRad — the oldest manufacturer of portable X-ray systems in the US. This new investment will allow National Imaging Solutions to support its customers by supplying them with DynaRad portable X-ray machines, including a mobile field X-ray device using nanotube technology.
News | Radiology Business | May 11, 2021
May 11, 2021 — ...
News | Radiation Therapy | May 06, 2021
May 6, 2021 — Individuals living with severe...
Research finds that a commonly used risk-prediction model for lung cancer does not accurately identify high-risk Black patients who could benefit from early screening

Getty Images

News | Lung Imaging | May 05, 2021
May 5, 2021 — Lung cancer is the third most common cance
A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Image used with permission of RSNA.

A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Read more about this case study. Image used with permission of RSNA.

Feature | Coronavirus (COVID-19) | May 03, 2021 | By Dave Fornell, Editor
While the mass COVID-19 vaccinat
Despite receiving high radiation doses to their tumors, lung cancer patients treated with technique that spares a large part of the esophagus did not develop severe inflammation of the esophagus

Getty Images

News | Lung Imaging | April 30, 2021
April 30, 2021 — For many patients with localized lung cance...